Health Canada Gives Update on AstraZeneca and Covishield Vaccines
By Stephen Nakrosis
Health Canada on Wednesday said it was offering an update to
Canadians and healthcare professionals on its ongoing safety review
of rare events of blood clots following immunization with the
AstraZeneca and Covishield Covid-19 vaccines.
Health Canada said after a thorough, independent assessment of
currently available data, it concluded "these very rare events may
be linked to use of the vaccine," adding "this is in line with the
findings of other regulators."
Health Canada said it updated the AstraZeneca and Covishield
vaccine labeling information to inform about these possible side
effects as well as to provide information about when to seek
Health Canada also said, based on a review of data from Europe
and the U.K. and AstraZeneca, no specific risk factors have been
identified, adding it isn't restricting the use of the vaccine at
Health Canada said its position is "that the safety of the
AstraZeneca vaccine meets its strict safety standards remains
valid, and the department is adjusting the product's labeling to
reflect the available scientific evidence."
AstraZeneca received authorization in Canada to manufacture its
ChAdOx1-S Covid-19 vaccine under the brand name AstraZeneca
Covid-19 Vaccine and Verity Pharmaceuticals and Serum Institute of
India, in collaboration with AstraZeneca, was authorized to
manufacture the vaccine under the brand name Covishield
AstraZeneca didn't immediately respond to a request for
Write to Stephen Nakrosis at email@example.com
(END) Dow Jones Newswires
April 14, 2021 12:32 ET (16:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.